Drugs / AMG 910
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04260191 | Jun 2020 → Jun 2022 | gastroesophageal adenocarcinoma | Amgen | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 910 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04260191 ↗ |
| Modality | Other / unclassified | “Half-life Extended Bispecific T-cell Engager AMG 910” NCT04260191 ↗ |
| Route | Intravenous | “short-term intravenous (IV) infusion” NCT04260191 ↗ |